tiprankstipranks
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
US Market
AVTX
Avalo Therapeutics
RESEARCH TOOLSreports

Avalo Therapeutics (AVTX) Financial Statements

1,047 Followers

Avalo Therapeutics Financial Overview

Avalo Therapeutics's market cap is currently $370.77M. The company's EPS TTM is $-0.75; its P/E ratio is -3.11; Avalo Therapeutics is scheduled to report earnings on March 23, 2026, and the estimated EPS forecast is $-1.20. See an overview of income statement, balance sheet, and cash flow financials.
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total Revenue$ 59.00K$ 441.00K$ 1.92M$ 18.05M$ 5.40M
Gross Profit$ -285.00K$ 807.00K$ 640.00K$ 14.62M$ 3.91M
Operating Income$ -72.92M$ -68.51M$ -27.35M$ -37.44M$ -82.13M
EBITDA$ -72.92M$ -68.34M$ -23.29M$ -37.27M$ -80.48M
Net Income$ -78.26M$ -35.13M$ -31.54M$ -41.66M$ -84.38M
Balance Sheet
Cash & Short-Term Investments$ 98.34M$ 134.55M$ 7.42M$ 13.17M$ 54.59M
Total Assets$ 116.46M$ 150.73M$ 20.99M$ 33.37M$ 80.21M
Total Debt$ 2.43M$ 568.00K$ 537.00K$ 19.95M$ 33.32M
Net Debt$ -13.43M$ -133.98M$ -6.88M$ 6.78M$ -21.27M
Total Liabilities$ 33.41M$ 17.70M$ 13.69M$ 44.28M$ 57.13M
Stockholders' Equity$ 83.05M$ 133.03M$ 7.30M$ -10.91M$ 23.08M
Cash Flow
Free Cash Flow$ -51.46M$ -49.06M$ -30.84M$ -26.85M$ -71.00M
Operating Cash Flow$ -51.46M$ -49.06M$ -30.68M$ -26.75M$ -70.89M
Investing Cash Flow$ -81.72M$ 356.00K$ -133.00K$ -95.00K$ -113.00K
Financing Cash Flow$ 14.59M$ 175.85M$ 25.04M$ -14.70M$ 106.76M
Currency in USD

Avalo Therapeutics Earnings and Revenue History

Income Statement >

Avalo Therapeutics Debt to Assets

Balance Sheet >

Avalo Therapeutics Cash Flow

Cash Flow >

Avalo Therapeutics Forecast EPS vs Actual EPS

Earnings >